Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Characteristics of breast cancer patients who received and did not receive postmastectomy radiotherapy

From: Number of negative lymph nodes can predict survival of breast cancer patients with four or more positive lymph nodes after postmastectomy radiotherapy

Characteristic n Without PMRT With PMRT p
(n = 234) (%) (n = 371) (%)
Age, years
  <35 64 20 (8.6) 44 (11.9) 0.197
  ≥35 541 214 (91.4) 327 (88.1)  
Menopausal status
  Premenopausal 400 153 (65.4) 247 (66.6) 0.763
  Postmenopausal 205 81 (34.6) 124 (33.4)  
Tumor size
  T1-T2 471 189 (80.8) 282 (76.0) 0.170
  T3-T4 134 45 (19.2) 89 (24.0)  
Nodal stage
  N2 321 139 (59.4) 182 (49.1) 0.013 *
  N3 284 95 (40.6) 189 (50.9)  
ER status
  Negative 285 112 (47.9) 173 (46.6) 0.767
  Positive 320 122 (52.1) 198 (53.4)  
PR status
  Negative 229 92 (39.3) 137 (36.9) 0.555
  Positive 376 142 (60.7) 234 (63.1)  
HER2 status
  Negative 376 136 (58.1) 240 (64.7) 0.105
  Positive 229 98 (41.9) 131 (35.3)  
Breast cancer subtype
  Luminal A 295 107 (45.7) 188 (50.7) 0.368
  Luminal B 130 53 (22.6) 77 (20.8)  
  HER2 positive 99 45 (19.3) 54 (14.5)  
  Triple negative 81 29 (12.4) 52 (14.0)  
Number of NLNs
  0-12 477 180 (76.9) 297 (80.0) 0.358
  12-39 128 54 (23.1) 74 (20.0)  
LNR
  < 0.20 42 29 (12.4) 13 (3.5) < 0.001*
  0.21-0.65 337 131 (56.0) 206 (55.5)  
  > 0.65 226 74 (31.6) 152 (41.0)  
  1. PMRT, post-mastectomy radiotherapy; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2; NLNs, negative lymph nodes; LNR, lymph node ratio.
  2. *p < 0.05 indicates a significant difference.